140 related articles for article (PubMed ID: 36889160)
1. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Focus (Am Psychiatr Publ); 2023 Oct; 21(4):420-429. PubMed ID: 38694999
[TBL] [Abstract][Full Text] [Related]
3. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
[TBL] [Abstract][Full Text] [Related]
4. Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Więdłocha M; Marcinowicz P; Komarnicki J; Tobiaszewska M; Dębowska W; Dębowska M; Szulc A
Front Psychiatry; 2024; 15():1398859. PubMed ID: 38742125
[TBL] [Abstract][Full Text] [Related]
5. Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.
Liester M; Wilkenson R; Patterson B; Liang B
Cureus; 2024 Apr; 16(4):e57654. PubMed ID: 38707115
[TBL] [Abstract][Full Text] [Related]
6. Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity.
Gałuszko-Węgielnik M; Jakuszkowiak-Wojten K; Wilkowska A; Cubała WJ
World J Biol Psychiatry; 2023 Nov; 24(9):849-853. PubMed ID: 37338035
[TBL] [Abstract][Full Text] [Related]
7. Intranasal oxytocin as an adjunct treatment among patients with severe major depression with and without comorbid borderline personality disorder.
Maoz H; Grossman-Giron A; Sedoff O; Nitzan U; Kashua H; Yarmishin M; Arad O; Tzur Bitan D
J Affect Disord; 2024 Feb; 347():39-44. PubMed ID: 37992767
[TBL] [Abstract][Full Text] [Related]
8. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
Singh B; Vande Voort JL; Pazdernik VK; Frye MA; Kung S
J Affect Disord; 2024 Apr; 351():534-540. PubMed ID: 38302067
[TBL] [Abstract][Full Text] [Related]
9. How changes in depression severity and borderline personality disorder intensity are linked - a cohort study of depressed patients with and without borderline personality disorder.
Söderholm JJ; Socada JL; Ekelund J; Isometsä E
Borderline Personal Disord Emot Dysregul; 2024 Feb; 11(1):3. PubMed ID: 38369499
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Esketamine among patients with treatment resistant depression in a 'real world' health-care setting in Israel.
Dvorak L; Bloemhof-Bris E; Shelef A; Halperin D; Wexler G; Talmon O; Feffer K
J Psychiatr Res; 2024 Jun; 174():66-72. PubMed ID: 38626563
[TBL] [Abstract][Full Text] [Related]
11. Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression.
Patarroyo-Rodriguez L; Pazdernik V; Vande Voort JL; Kung S; Singh B
J Affect Disord; 2024 Mar; 349():272-276. PubMed ID: 38199421
[TBL] [Abstract][Full Text] [Related]
12. Borderline Personality Features in Patients With Persistent Depressive Disorder and Their Effect on CBASP Outcome.
Konvalin F; Grosse-Wentrup F; Nenov-Matt T; Fischer K; Barton BB; Goerigk S; Brakemeier EL; Musil R; Jobst A; Padberg F; Reinhard MA
Front Psychiatry; 2021; 12():608271. PubMed ID: 33790813
[No Abstract] [Full Text] [Related]
13. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder.
Fineberg SK; Choi EY; Shapiro-Thompson R; Dhaliwal K; Neustadter E; Sakheim M; Null K; Trujillo-Diaz D; Rondeau J; Pittaro GF; Peters JR; Corlett PR; Krystal JH
Neuropsychopharmacology; 2023 Jun; 48(7):991-999. PubMed ID: 36804489
[TBL] [Abstract][Full Text] [Related]
14. Study on the Correlation between Hcy and Hs-CRP Levels and Cognitive Function in Patients with Bipolar Disorder and Borderline Personality Disorder.
Wang C; Lv L; Xin B; Li N; Wang J; An C; Zhang K
Actas Esp Psiquiatr; 2024 Apr; 52(2):99-106. PubMed ID: 38622012
[TBL] [Abstract][Full Text] [Related]
15. Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.
Rodrigues NB; Chen-Li D; Di Vincenzo JD; Juneja A; Pinder BD; McIntyre RS; Rosenblat JD
J Psychopharmacol; 2024 Apr; 38(4):375-381. PubMed ID: 38477185
[TBL] [Abstract][Full Text] [Related]
16. Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report.
Garel N; Greenway KT; Dinh-Williams LL; Thibault-Levesque J; Jutras-Aswad D; Turecki G; Rej S; Richard-Devantoy S
Neuropsychopharmacology; 2023 Nov; 48(12):1769-1777. PubMed ID: 37532888
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report.
Joseph B; Nunez NA; Kung S; Vande Voort JL; Pazdernik VK; Schak KM; Boehm SM; Carpenter B; Johnson EK; Malyshev G; Smits N; Adewunmi DO; Brown SK; Singh B
Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631079
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Depressive Symptom Self-Reported Measures in the Texas Youth Depression and Suicide Research Network (TX-YDSRN).
Nandy K; Rush AJ; Carmody T; Kennard BD; Emslie GJ; Slater H; Mayes TL; DeFilippis M; Garza C; Storch EA; Wakefield SM; Trivedi MH
J Clin Psychiatry; 2023 Dec; 85(1):. PubMed ID: 38127311
[No Abstract] [Full Text] [Related]
19. Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans.
Miller EA; Afshar HT; Mishra J; McIntyre RS; Ramanathan D
Psychiatry Res; 2024 May; 335():115858. PubMed ID: 38547599
[TBL] [Abstract][Full Text] [Related]
20. The relationship between borderline personality disorder and major depression in later life: acute versus temperamental symptoms.
Galione JN; Oltmanns TF
Am J Geriatr Psychiatry; 2013 Aug; 21(8):747-56. PubMed ID: 23567384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
